David Lennon
, CEO, Whitehawk Therapeutics
Dr. Lennon joined the Company in October 2023 as President and CEO and member of the board of directors. Dr. Lennon brings more than twenty years of experience leading global biotechnology and pharmaceutical teams, with significant expertise in development and commercialization in oncology. Most recently, Dr. Lennon served as Chief Executive Officer and member of the board of directors at Satellite Bio, a privately held regenerative medicine company. In his prior role he served for 15 years at Novartis, most recently as President, Novartis Gene Therapies where he was responsible for development, approval and launch of the blockbuster Zolgensma®, the first systemic gene therapy for the rare disease spinal muscular atrophy. In prior roles with Novartis, he held leadership roles in Novartis Oncology for the U.S. and Japan regions, having also held key commercial leadership positions in the United States, China and Switzerland. Dr. Lennon started his career as a scientist, cloning a gene important for genomic stability and prevention of cancer. He holds a PhD in Molecular Medicine from Weill Cornell Medical College of Cornell University and a BA in Biophysics from Columbia College of Columbia University. After completing his PhD, Dr. Lennon joined McKinsey & Company, focusing on R&D strategy and strategic transactions in the pharmaceutical industry.
